Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
- Conditions
- LeukemiaChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2025-03-14
- Target Recruit Count
- 29
- Registration Number
- NCT03722407
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
- Conditions
- Leptomeningeal DiseaseLeptomeningeal Metastases
- Interventions
- Radiation: Whole Brain Radiotherapy
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2025-05-22
- Target Recruit Count
- 16
- Registration Number
- NCT03719768
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
- Conditions
- Resectable Pancreatic CancerPancreatic Cancer
- Interventions
- Procedure: Surgical Resection
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
- Conditions
- Colorectal CancerMetastatic Colorectal CancerColon Cancer
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2025-04-17
- Target Recruit Count
- 52
- Registration Number
- NCT03712943
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2025-05-23
- Target Recruit Count
- 23
- Registration Number
- NCT03686488
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients
- Conditions
- AnxietyGeneralized Anxiety DisorderDepressive DisorderMajor Depressive DisorderCancerDepression
- Interventions
- Diagnostic Test: DNA-guided choice of therapyOther: Clinical management
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2025-04-13
- Target Recruit Count
- 99
- Registration Number
- NCT03674138
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2023-02-15
- Target Recruit Count
- 19
- Registration Number
- NCT03663166
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸UNC Limeberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Duke University, Durham, North Carolina, United States
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
- Conditions
- Oropharyngeal Cancer
- Interventions
- Radiation: Radiotherapy fractionation
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2025-04-17
- Target Recruit Count
- 55
- Registration Number
- NCT03656133
- Locations
- 🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
- Conditions
- HER-2 Gene AmplificationBreast Cancer, MaleBreast CancerHER2-positive Breast CancerHER2 Positive Breast CarcinomaHER-2 Protein OverexpressionBreast Cancer Female
- Interventions
- Biological: HER2 DC1 Vaccine
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2022-04-25
- Target Recruit Count
- 16
- Registration Number
- NCT03630809
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
- Conditions
- Osteosarcoma RecurrentSarcomaOsteosarcoma in ChildrenOsteosarcoma
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2025-04-04
- Target Recruit Count
- 21
- Registration Number
- NCT03628209
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States